

VPM helps facilitate fast track designation for Memo Therapeutics AG's AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients

Hannover, Germany, May 11, 2023 – Vakzine Projekt Management GmbH (VPM), a German pharmaceutical development consultancy and service provider, announced today that it has supported Memo Therapeutics AG (MTx) during the process for receiving fast track designation from the U.S. Food and Drug Administration (FDA) for the novel human monoclonal antibody, AntiBKV, developed by MTx for the treatment of BK viremia in kidney transplant recipients.

BK viremia is a common and serious complication of kidney transplantation, caused by reactivation of BK polyomavirus (BKV) infection. BK viremia can lead to BK virus-associated nephropathy (BKVAN), which can result in graft loss and reduced survival. There is currently no approved therapy for BK viremia or BKVAN.

AntiBKV is a fully human antibody that binds to and neutralizes BKV, preventing viral replication and tissue damage. AntiBKV was discovered using MTx's proprietary Dropzylia platform, which enables rapid identification of antibodies from natural immune responses of patients. AntiBKV has shown promising results in a Phase I clinical trial in healthy volunteers, demonstrating safety, tolerability, and pharmacokinetics. The pivotal phase II/III trial has started to recruit renal transplant patients in the USA.

VPM has supported MTx's AntiBKV development from the very start, including the efficient design and implementation of the ongoing phase II/III trial in the US. In addition, VPM supported MTx during the process to obtain Fast Track designation from the FDA. Fast Track designation accelerates the development and the review of drugs that treat serious diseases. Fast Track designation enables more frequent interactions with the FDA, rolling review of the Biologics License Application (BLA), and eligibility for priority review and accelerated approval.

Dr. Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG said: "We are very pleased to receive Fast Track designation from the FDA for AntiBKV, which reflects the high unmet medical need and the potential of our antibody to improve outcomes for kidney transplant recipients. We are grateful to VPM for their outstanding support and guidance throughout our development journey. With their expertise and network, we were able to advance our antibody from discovery to clinical trials in a fast and efficient manner."

Dr. Gerald Parzmair, Chief Scientific Officer of VPM added: "We are proud to be part of this success story and to contribute to the development of a novel and innovative therapy for BK viremia. We believe that AntiBKV has the potential to become a breakthrough treatment for kidney transplant recipients who suffer from this life-threatening complication. We look forward to continuing our collaboration with MTx and supporting them in their next steps towards regulatory approval and market access."

About VPM

Vakzine Projekt Management GmbH (VPM) is a German consultancy and service provider established in 2002. Within the last two decades, VPM has successfully managed the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM clients are small, medium, and large biopharmaceutical

enterprises, as well as private funding organizations, and research groups. VPM brought their products from preclinical stage through clinical phases I-II-III up to approval.

Since 2012 VPM has its consulting and service business. Based on its in-depth experience and a strong network of reliable partners, VPM offers tailor-made hands-on services. The consulting and service offers refer to the entire product development phases as VPM has successfully progressed its own products along the development value chain.

For more information, please visit www.vpm-consult.com

About Memo Therapeutics AG

Memo Therapeutics AG (MTx) is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx's lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. MTx's pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus (CMV), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical.

The product pipeline derives from MTx's industry-leading throughput and functional screening capabilities, which can cover the entire antibody repertoire. Using its immortal cell libraries and unique nano droplet technology, MTx identifies and isolates the most potent antibodies based on functionality at an unprecedented rate, including discovering ultra-rare antibodies that competing technologies fail to identify. MTx is a private company located in Schlieren / Zurich, Switzerland.

For more information, please visit www.memo-therapeutics.com

Contact

VPM

Dr. Leander Grode, CEO

Tel: +49 511 16 99 08 19

info@vakzine-manager.de